Background: The objective of this study was to assess the impact of perioperative transfusion on the prognosis of patients who underwent complete (R0) resection of oral squamous cell carcinoma and reconstruction by microvascular flaps.
Methods: By following an inclusion and exclusion protocol, 223 patients were included in the study who underwent R0 resection of oral squamous cell carcinoma and reconstruction by microvascular flaps at a single center. Clinical and pathologic factors as well as transfusion data were retrieved from a prospective database and analyzed retrospectively. Survival data were assessed using the method of Kaplan and Meier. For multivariate analysis the accelerated failure time model (Weibull distribution) was chosen.
Results: The overall survival rate was 71% at 1 year, 67% at 3 years, and 55% at 5 years. In univariate analysis, age (P = .003), tumor size (P = .005), lymph node status (P = .008), tumor differentiation (P = .008), transfusion (P = .006), American Society of Anesthesiologists (ASA) class (P = .001), and mandibular reconstruction (P = .045) were associated significantly with overall survival. Multivariate analysis identified only age, histopathologic differentiation, and ASA class as independent risk factors (P < .001, P = .04, and P = .049, respectively). Age was identified as the strongest independent predictor for overall survival (hazards ratio for each 13-year increase in age, 1.97; 95% confidence interval, 1.36-2.85).
Conclusions: Transfusion of >4 U of blood did not appear to influence overall survival in patients who underwent primary surgery for oral squamous cell carcinoma. Because age and ASA class evolved as the strongest predictors of shortened overall survival, associated comorbidities may require more attention, particularly in elderly or socially deprived patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/cncr.24132 | DOI Listing |
Int Dent J
January 2025
Department of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam University Medical Centre, Location Vrije Universiteit and Academic Centre for Dentistry Amsterdam (ACTA), Amsterdam, The Netherlands. Electronic address:
Objective: To assess the knowledge, attitude, and practice of Dutch dentists on oral leukoplakia (OL) and to what extent these aspects are related to whether or not dentists regularly monitor patients with OL.
Material And Methods: A self-developed questionnaire was distributed via a web survey among a sample of dentists participating in an intervision program. Of 1626 invited dentists, 437 (26.
Oral Surg Oral Med Oral Pathol Oral Radiol
December 2024
Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre-RS, Brazil. Electronic address:
Objective: actinic cheilitis (AC) is a potentially malignant disorder of the lip vermillion. The study of effective therapeutic options is of the utmost importance to prevent the development of lip squamous cell carcinoma. This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.
View Article and Find Full Text PDFEur J Pharmacol
January 2025
Department of Conservative Dentistry & Endodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, Tamil Nadu, India. Electronic address:
Oral squamous cell carcinoma (OSCC) remains a major cause of morbidity and mortality worldwide with high recurrence rates and resistance to conventional therapies. Recent studies have highlighted the pivotal role of oral cancer stem cells (OCSCs) in driving treatment resistance and tumor recurrence. OCSCs possess unique properties, including self-renewal, differentiation potential, and resistance to chemotherapy and radiotherapy, which contribute to their ability to survive treatment and initiate tumor relapse.
View Article and Find Full Text PDFOral Oncol
January 2025
Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.
Head and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of malignancies with multifactorial aetiologies. High-risk human papillomavirus (hrHPV) infections, particularly HPV16, and the dysregulation of telomerase activity, specifically through its catalytic subunit, telomerase reverse transcriptase (TERT) are among the key contributors to HNSCC development and progression. HPV promotes oncogenesis via the E6 and E7 oncoproteins, which inactivate tumour suppressors TP53 and RB1, leading to unchecked cellular proliferation.
View Article and Find Full Text PDFOral Oncol
January 2025
Value and Implementation, Outcomes Research, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
Background: Pembrolizumab with/without platinum + 5-FU is approved for the first-line (1L) treatment of R/M HNSCC, and its monotherapy use requires PD-L1 Combined Positive Score (CPS) ≥ 1. We aimed to understand PD-L1 testing patterns and associations with patient characteristics and treatment choice in R/M HNSCC.
Methods: Adults with R/M HNSCC initiating 1L systemic therapy were included from a U.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!